VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb. The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products.
The milestone marks a significant step for VERAXA’s pipeline, which focuses on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company leverages technologies originating from the European Molecular Biology Laboratory (EMBL). VXA-222’s “AND-gate” mechanism is designed to enhance tumor selectivity by requiring simultaneous binding to two antigens, potentially reducing off-target effects common in traditional ADCs.
VERAXA’s proprietary BiTAC format and linker technology are central to its approach. The company emphasizes quality-by-design principles in its development process. The advancement of VXA-222 could open new avenues for treating solid tumors that are difficult to address with conventional therapies.
For more details, the full press release is available at https://ibn.fm/qMRuJ. Updates on VRXA are posted in the company’s newsroom at https://ibn.fm/VRXA.
